Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.

Tsofack SP, Garand C, Sereduk C, Chow D, Aziz M, Guay D, Yin HH, Lebel M.

Mol Cancer. 2011 Nov 25;10:145. doi: 10.1186/1476-4598-10-145.

2.

An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.

Garand C, Guay D, Sereduk C, Chow D, Tsofack SP, Langlois M, Perreault E, Yin HH, Lebel M.

Cancer Sci. 2011 Jul;102(7):1410-7. doi: 10.1111/j.1349-7006.2011.01948.x. Epub 2011 May 5.

3.

MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1.

Guo Y, Pang Y, Gao X, Zhao M, Zhang X, Zhang H, Xuan B, Wang Y.

Cancer Biomark. 2017;18(1):1-9. doi: 10.3233/CBM-160650.

PMID:
28035913
4.

The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells.

Guay D, Garand C, Reddy S, Schmutte C, Lebel M.

Cancer Sci. 2008 Apr;99(4):762-9. doi: 10.1111/j.1349-7006.2008.00739.x. Epub 2008 Feb 27.

5.

Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.

Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A, Neamati N.

Int J Oncol. 2006 Jul;29(1):225-35.

PMID:
16773204
6.

The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures.

Guay D, Evoy AA, Paquet E, Garand C, Bachvarova M, Bachvarov D, Lebel M.

Int J Biochem Cell Biol. 2008;40(11):2492-507. doi: 10.1016/j.biocel.2008.04.011. Epub 2008 May 15.

PMID:
18571458
7.

siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.

Montazami N, Kheir Andish M, Majidi J, Yousefi M, Yousefi B, Mohamadnejad L, Shanebandi D, Estiar MA, Khaze V, Mansoori B, Baghbani E, Baradaran B.

Cell Mol Biol (Noisy-le-grand). 2015 May 28;61(2):98-103.

PMID:
26025411
8.

Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.

El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC.

Gastroenterology. 2011 Aug;141(2):663-73. doi: 10.1053/j.gastro.2011.04.055. Epub 2011 Apr 30.

PMID:
21683075
9.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9. Epub 2005 Aug 2.

PMID:
16075278
10.

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.

Ginés A, Bystrup S, Ruiz de Porras V, Guardia C, Musulén E, Martínez-Cardús A, Manzano JL, Layos L, Abad A, Martínez-Balibrea E.

PLoS One. 2015 May 8;10(5):e0123830. doi: 10.1371/journal.pone.0123830. eCollection 2015.

11.

MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.

Tentori L, Muzi A, Dorio AS, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G.

Cancer Chemother Pharmacol. 2013 Jul;72(1):117-25. doi: 10.1007/s00280-013-2175-0. Epub 2013 May 1.

PMID:
23636450
12.

p54nrb/NONO regulates cyclic AMP-dependent glucocorticoid production by modulating phosphodiesterase mRNA splicing and degradation.

Lu JY, Sewer MB.

Mol Cell Biol. 2015 Apr;35(7):1223-37. doi: 10.1128/MCB.00993-14. Epub 2015 Jan 20.

13.

miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.

Chai H, Liu M, Tian R, Li X, Tang H.

Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):217-25. doi: 10.1093/abbs/gmq125. Epub 2011 Jan 17.

PMID:
21242194
14.

Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.

Sharp SY, O'Neill CF, Rogers P, Boxall FE, Kelland LR.

Eur J Cancer. 2002 Nov;38(17):2309-15.

PMID:
12441268
15.

miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.

Tan S, Shi H, Ba M, Lin S, Tang H, Zeng X, Zhang X.

Int J Mol Med. 2016 Apr;37(4):1030-8. doi: 10.3892/ijmm.2016.2492. Epub 2016 Feb 18.

PMID:
26935807
16.

Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.

Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto K, Tsujimoto M, Bay BH.

Int J Oncol. 2010 Aug;37(2):483-92.

PMID:
20596676
17.

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.

Martinez-Cardús A, Martinez-Balibrea E, Bandrés E, Malumbres R, Ginés A, Manzano JL, Taron M, Garcia-Foncillas J, Abad A.

Mol Cancer Ther. 2009 Jan;8(1):194-202. doi: 10.1158/1535-7163.MCT-08-0659.

18.

Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.

Ekblad L, Kjellström J, Johnsson A.

Anticancer Drugs. 2010 Jun;21(5):523-31. doi: 10.1097/CAD.0b013e328337b867.

PMID:
20168208
19.

Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.

Virag P, Perde-Schrepler M, Fischer-Fodor E, Tatomir C, Dorneanu SA, Cernea VI, Irimie A.

Anticancer Drugs. 2012 Nov;23(10):1032-8.

PMID:
22614106
20.

Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4147-53.

Supplemental Content

Support Center